References: 1. JORNAY PM® [package insert]. Ironshore Pharmaceuticals &
Development, Inc.
2. Childress AC, Cutler AJ, Marraffino A, et al. A randomized, double-blind, placebo-controlled
study of
HLD200, a delayed-release and extended-release methylphenidate, in children with
attention-deficit/hyperactivity disorder: an evaluation of safety and efficacy throughout the day and
across settings. J Child Adolesc Psychopharmacol. 2020;30(1):2-14.
3. Pliszka SR, Wilens TE, Bostrom S, et al. Efficacy and safety of HLD200, delayed-release and
extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. J Child
Adolesc Psychopharmacol. 2017;27(6):474-482.
4. Gomeni R, Komolova M, Incledon B, Faraone SV. Model-based approach for establishing the
predicted
clinical response of a delayed-release and extended-release methylphenidate for the treatment of
attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2020;40(4):350-358.
5. Childress AC, Uchida CL, Po MD, DeSousa NJ, Incledon B. A post hoc comparison of prior ADHD
medication dose and optimized delayed-release and extended-release methylphenidate dose in a pivotal
phase III trial. Clin Ther. 2020;42(12):2332-2340.
6. Childress A, Mehrotra S, Gobburu J, McLean A, DeSousa NJ, Incledon B. Single-dose
pharmacokinetics of
HLD200, a delayed-release and extended-release methylphenidate formulation, in healthy adults and in
adolescents and children with attention-deficit/hyperactivity disorder. J Child Adolesc
Psychopharmacol.
2018;28(1):10-18.
7. Gomeni R, Tan D, Sallee R, Incledon B. A model-based pharmacokinetic comparison of
delayed-release/extended-release methylphenidate to extended-release methylphenidates with
immediate-release supplementation. Poster presented at: The American Professional Society of ADHD and
Related Disorders (APSARD) Annual Meeting; January 15-17, 2021.
8. Liu T, Gobburu JVS, Po MD, et al. Pharmacokinetics of HLD200, a delayed-release and
extended-release
methylphenidate: evaluation of dose proportionality, food effect, multiple-dose modeling, and
comparative bioavailability with immediate-release methylphenidate in healthy adults. J Child Adolesc
Psychopharmacol. 2019;29(3):181-191.
9. Katzman A, Otcheretko V, Po M, et al. Adverse events during dosing of
delayed-release/extended-release methylphenidate: learnings from the open-label phase of a registration
trial and a real-world postmarketing surveillance program. Clin Ther. 2023;45:1212-1221.
10. Faraone SV, DeSousa NJ, Komolova M, et al. Functional impairment in youth with ADHD:
normative data
and norm-referenced cutoff points for the Before School Functioning Questionnaire and the Parent Rating
of Evening and Morning Behavior Scale, Revised. J Clin PsychiatryJ. 2020;81(1):19m12956.
11. APTENSIO XR [package insert]. Rhodes Pharmaceuticals; 2019.
12. AZSTARYS [package insert]. Corium, Inc.; 2021.
13. CONCERTA [package insert]. Janssen Pharmaceuticals, Inc.; 2021.
14. COTEMPLA XR-ODT [package insert]. Aytu BioPharma, Inc.; 2023.
15. FOCALIN XR [package insert]. Novartis Pharmaceuticals Corporation; 2021.
16. METADATE CD [package insert]. UCB, Inc.; 2013.
17. METADATE ER [package insert]. UCB, Inc.; 2014.
18. QUILLIVANT XR [package insert]. NextWave Pharmaceuticals, Inc.; 2021.
19. QUILLICHEW ER [package insert]. NextWave Pharmaceuticals, Inc.; 2021.
20. RITALIN LA [package insert]. Novartis Pharmaceuticals Corporation; 2021.
21. ADZENYS XR-ODT [package insert]. Aytu BioPharma, Inc.; 2022.
22. ADDERALL XR [package insert]. Shire US Inc.; 2013.
23. DEXEDRINE [package insert]. GlaxoSmithKline; 2007.
24. DYANAVEL XR [package insert]. Tris Pharma Inc.; 2022.
25. MYDAYIS [package insert]. Takeda Pharmaceuticals U.S.A., Inc.; 2022.
26. VYVANSE [package insert]. Takeda Pharmaceuticals U.S.A., Inc.; 2022.
27. Incledon B, Incledon C, Gomeni R, et al. Effect of colonic absorption on the pharmacokinetic
properties of delayed-release and extended-release methylphenidate: in vivo, in vitro, and modeling
evaluations. Clin Pharm Drug Dev. 2022;11(8):966-975.
28. Data on file. HLD200-108; Ironshore Pharmaceuticals & Development, Inc.; 2016.
29. Data on file. HLD200-107; Ironshore Pharmaceuticals & Development, Inc.; 2016.
30. Wigal SB, Gupta S, Guinta D, Swanson JM. Reliability and validity of the SKAMP rating scale
in a
laboratory school setting. Psychopharmacol Bull. 1998;34(1):47-53.
31. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R. ADHD Rating Scale-IV: Checklists, norms, and
clinical
interpretation. New York: Guilford; 1998.
Pivotal Study
1 - SKAMP
Assessment30
Pivotal Study 2
- ADHD-RS-IV
Assessment31
